Vitamin D and HbA1c Levels in Diabetic Patients With CKD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02906319|
Recruitment Status : Completed
First Posted : September 20, 2016
Last Update Posted : September 20, 2016
|Condition or disease|
|Vitamin D Deficiency Diabetes Mellitus|
This was a cross sectional study using consecutive sampling methodology for participant recruitment. It was carried out at the specialized diabetic, renal, and general outpatient clinics in the University of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia.
Serum 25(OH)D levels were determined by using direct chemiluminesent immunoassay (ADVIA Centaur XP; Siemens Healthcare Diagnostics, Tarrytown, New York, USA). Serum HbA1c levels were determined using high-pressure liquid chromatography (Variant™ II Turbo; Bio-Rad, Hercules, California, USA).
Data collected will be analyzed using Statistical Package for Social Sciences SPSS version 23.0 for Windows, version 23.0 (IBM Corp., Armonk, New York, USA).
|Study Type :||Observational|
|Actual Enrollment :||100 participants|
|Official Title:||Association Between Serum 25-hydroxyvitamin D Levels and Glycated Haemoglobin in Diabetic Patients With Chronic Kidney Disease|
|Study Start Date :||September 2015|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||July 2016|
- 25-hydroxyvitamin D levels [ Time Frame: Within 2 weeks from enrolment ]The unit of measure was nmol/L. The detection limit of the device was <10 nmol/L. A mean value of 5 nmol/L were taken for results reported as <10nmol/L.
- HbA1c levels [ Time Frame: Within 2 weeks from enrolment ]The unit of measure was percentage (using NGSP standarization).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02906319
|Principal Investigator:||Yong Muh Ng, MMed||University of Malaya|